We would love to hear your thoughts about our site and services, please take our survey here.
A new report from Tufts Medical Center’s New Drug Development Paradigms (NEWDIGS) program shows that cell and gene therapies for orphan diseases and hematological cancers are two to 3.5 times more likely to be successful than other types of treatments for similar conditions, or as compared to the entire drug pipeline.
CAR-T/TCR therapies for blood cancers were three times more likely to be approved when entering phase 1 compared to the average oncology drug and over two times more likely than the average hematological oncology drug, it concluded.
Listening to Novartis yesterday making it very clear that Radiotherapy was one of their key growth areas, in Avacta’s case, the majors only have one problem:
Who goes first ?
However with AVA6000 and AVA3996,Cohort and the rest of the AVA family- Nasdaq could be round the corner sooner rather than later!
NY will be up early and size buyers will step it up a gear.
Watch out for Dr. Tap seen shaking hands with the FDA, two weeks works!!
Roche to gain gut disease drug in $7.1B deal for Roivant subsidiary
The Swiss pharmaceutical company has agreed to buy Telavant, a company set up by Roivant and Pfizer to develop a promising inflammatory bowel disease treatment.
Eli Lilly have already made 6 transactions this year, but market believes it will not stop them talking to PointBiopharma.
Eli Lilly could also approach Avacta for them to assist in such conversations, because of Avacta’s jv’s with PointBiopharma.
More to come from ESMO no doubt.
Did you all see this :
TOKYO, Oct 19 (Reuters) - Drugmaker Merck will pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs, they said, in a deal that could be worth up to $22 billion to the Japanese firm depending on the success of the cell-targeting therapies.
French pre-clinical biotech Mablink Biosciences has confirmed earlier rumors that it has agreed to a takeover bid from acquisition-hungry US pharma major Eli Lilly .
This is the 6th deal by Lilly this year.
They are presenting at ESMO